03 January 2020
Visiongain has published a New pharma report of Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies.
The Global Anaesthesia Drugs Market is estimated to grow at a CAGR of 3.9% from 2019 to 2024, dominated by the local anaesthesia submarket. The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population.
This report profiled the selected companies: Abbott Laboratories, AbbVie, Aspen Pharmacare, AstraZeneca, B. Braun Melsungen AG, Baxter International, Boehringer Ingelheim, Eisai, Endo International and other companies.
The lead analyst commented that "Advancements in the anaesthesia drug delivery methods, such as jet injection, inhalation and computer-controlled anaesthesia delivery systems will further encourage the general anaesthesia drugs industry. Over the years, the emergence of new medications, technology, and knowledge has revolutionized perioperative medicine, and as a consequence, interest in how these changes affect anaesthetic care and practice has emerged."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.